Drugs (2017) 77:1929–1933 https://doi.org/10.1007/s40265-017-0845-7 Springer International Publishing AG, part of Springer Nature 2017 Dear Reader As we reach the ﬁnal issue of Drugs for 2017, I wish to reﬂect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content. 2017 was a successful year for Drugs. Over 150 articles have been published, and as of the end of October, 28 of these have been downloaded from SpringerLink over 1000 times. Topics covered by these popular articles included the language of biosimilars, targeting of new signalling pathways in asthma, immune disorders and cancer, appropriate use of anti- epileptics, proton pump inhibitors and antimicrobials, chimeric antigen receptor (CAR)-T cells, nanobiotechnology in pain management, and new developments in the drug treatment of diabetes, psoriasis and hepatitis B. Social media sharing of information is becoming more important and is another metric with which to measure the reach of articles. This year several articles published in Drugs scored over 20 on the Altmetric system. The quality of articles published in the journal is also reﬂected in its most recent (2016) impact factor of 5.000 (up from 4.883 in 2015).
Drugs – Springer Journals
Published: Nov 10, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera